A portrait of a doctor in surgery.
about us

WREN - The Origin of the Laboratory Name

Sir Christopher Wren embodies the concept of integrating different forms of knowledge and the arts to solve clinical problems that result in a clinical benefit. He was among the first to draw blood from human veins and helped developed mathematics to a fine art that could then be applied to understanding science. The “W” of Wren also embraces the name of Watson, inspiration of the basis of human DNA and role of genetics in disease.

Wren therefore symbolizes the principle of molecular genomics in understanding the architecture of disease and is exemplified by our approach of using intricate genetic tools and complex biomathematics to solve critical clinical questions using a drop of blood.
Our values

The Science

We are committed to performing and using great science.


We are innovative and pioneering in our techniques, application and approach.


We are open, connected and collaborative.


We strive for excellence in all things scientific and clinical-related.

Making the Difference

Our principal focus is to make a meaningful impact in the lives of cancer patients and to help with the COVID pandemic.
A portrait of Irvin M. Modlin,
Clinical and Scientific Consultant.

Irvin M. Modlin

Clinical and Scientific Consultant

Irvin M. Modlin, MD, PhD, DSc, an expert in the area of Neuroendocrine Tumor (NET) disease, is the Medical Director of Wren Laboratories and is a Clinical Consultant to the testing laboratory. He is formerly the director of the Gastrointestinal Pathobiology Research Group and is now an Emeritus Professor at Yale University. Dr Modlin has studied Neuroendocrine Tumor (NET) disease for three decades, authored many of the seminal publications on the subject and has extensive global experience in novel therapeutic and diagnostic advances. His background also includes gastrointestinal surgery, endocrine surgery, endoscopy and gut hormone physiology. With over five hundred peer-reviewed publications and more than thirty years of experience working with neuroendocrine tumor and carcinoid patients, he has recently focused on the development and implementation of novel molecular testing protocols for these cancers.

A portrait of Mark Kidd, Scientific and Laboratory Director.

Mark Kidd

Scientific and Laboratory Director

Mark Kidd, PhD, DABCC has worked and published extensively in the area of Neuroendocrine Tumor (NET) disease, and is the Scientific Director of Wren Laboratories. He is credentialed with the American Board of Clinical Chemistry in Molecular Diagnostics to perform and report on molecular-based diagnostic testing. He is also the CLIA-certified Laboratory Director and Technical Consultant for Wren Laboratories (07D2081388). His professional and academic research interests have focused on the biology of neuroendocrine cells and development of tumor models of the disease. Dr. Kidd's publications cover diverse areas including global gene analysis, tissue microarrays, tumor biology, bacterial genetics as well as gastric and pancreatic pathology. Dr. Kidd has more than fifteen years of molecular and cancer biology laboratory experience specifically focused on NETs.

A dye marker on agarose gel used to separate DNA by a female scientist.

The story so far.

The history of Wren Laboratories:
Jul 2014
Laboratory establishment, Branford, Connecticut.
Oct 2014
Clinical laboratory certification in Connecticut and CLIA license for the NETest.
May 2018
California Department of Health Permit - NETest.
Aug 2018
New York State Department of Health Permit – NETest.
Oct 2018
Development of the PPQ – PRRT Predictive Quotient.
Nov 2019
Set-up of NETesting at Sarah Cannon, UK.
Aug 2019
FDA-EUA for nasopharyngeal swab SARS-CoV-2 diagnosis.
Oct 2020
FDA-EUA for COVID-19 PCR saliva testing.

Customers are thrilled with the results we have achieved.

Contact Our Team